ESR1 and breast carcinoma: We further demonstrate the druggable potential of SEMA3C by using the B1SP Fc fusion protein, a SEMA3C pathway inhibitor that has displayed inhibitory effects on the growth and signaling of ER+ breast cancer cells comparable with those observed during SEMA3C silencing.